Significant Advancements in TAVI Presented at EuroPCR 2025
The recent presentation of the Myval THV series at EuroPCR 2025 marks a significant milestone in cardiac care. Meril Life Sciences shared groundbreaking one-year results from the LANDMARK trial, highlighting the safety and effectiveness of their innovative balloon-expandable valve technology.
The LANDMARK trial represents a pivotal moment in valve research, being the first randomized non-inferiority trial that compares the Myval THV series with other leading treatments. The study took place at a prestigious cardiology conference, showcasing Meril's commitment to advancing medical technology within this field.
Key Findings from the LANDMARK Trial
The Myval THV series demonstrated promising outcomes, showing non-inferiority in terms of the one-year clinical efficacy composite endpoint. With results indicating Myval THV Series at 13% versus 13.1% for contemporary treatments, it was clear that the Myval holds its ground against established competitors.
Additionally, when considering quality of life (QoL) alongside clinical efficacy, outcomes remained comparable with Myval THV Series reported at 19.5% compared to 22.7% for contemporary THVs, further validating the valve's effectiveness.
According to the data shared, survival rates exhibited nearly identical results, indicating that Myval THV series maintained a survival rate of 92.8% compared to 92.9% for the contemporary treatments. Alongside this, improvements in QoL reinforced the safety and durability of Myval THV series in everyday clinical applications.
Expert Insights from the Trial Leaders
Professor Patrick Serruys, the Chairman and Study Director of the LANDMARK trial, emphasized the significance of the trial's design and its adherence to VARC-3 standards. He remarked that this trial represents a new era in comparative valve research, a pivotal advancement for patients receiving TAVI.
In his statement, Professor Andreas Baumbach, the Global Principal Investigator, commended the structured approach of the trial. He noted that for the first time, Myval was benchmarked against both balloon-expandable and self-expanding platforms, ensuring comprehensive evaluation of its performance in a rigorous setting.
Furthermore, Mr. Sanjeev Bhatt, Senior Vice President – Corporate Strategy at Meril, highlighted the trial as not just a milestone for the company but for the global TAVI community. The results reaffirm the Myval THV series as a next-generation cardiac solution that delivers consistent safety and improved patient outcomes.
With a focus on long-term insights, the trial is designed to follow patients for up to ten years, collecting data on clinical outcomes and valve durability as part of its comprehensive evaluation.
About the LANDMARK Trial
The LANDMARK trial involved a robust cohort of 768 patients, all of whom were undergoing Transcatheter Aortic Valve Implantation (TAVI) for symptomatic severe aortic stenosis. The trial's design provided a thorough analysis of the Myval THV series’ performance, examining its efficacy and safety among various patient demographics across multiple international sites.
Results of the primary endpoints have already been published in influential medical journals, demonstrating the high caliber of research represented in this trial, which further solidifies the Myval series’ reputation in valve technology.
About Meril Life Sciences
As a global medical device company headquartered in India, Meril Life Sciences is dedicated to innovation in healthcare. They focus on delivering top-tier medical technology across 135 countries. Their commitment to quality and research ensures that they remain at the forefront of transforming healthcare practices worldwide.
Frequently Asked Questions
What is the LANDMARK trial?
The LANDMARK trial compares the Myval THV series with other contemporary heart valve treatments to evaluate safety and efficacy.
What were the main outcomes of the trial?
The Myval THV series showed non-inferiority in clinical efficacy and comparable survival rates to other treatments.
How long will patients be followed in the study?
Patients in the LANDMARK trial will be followed for up to ten years to gather comprehensive long-term data.
Who are the leading experts involved in the trial?
Key figures like Professor Patrick Serruys and Professor Andreas Baumbach have been instrumental in leading the LANDMARK trial.
What is the significance of Myval THV series in TAVI procedures?
The Myval THV series offers a next-generation solution that emphasizes safety and improved quality of life for patients undergoing TAVI.
